How many days before anesthesia should GLP‑1 receptor agonists be discontinued, specifying differences for daily versus weekly formulations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

GLP-1 Receptor Agonist Discontinuation Before Anesthesia

For elective surgery requiring anesthesia, discontinue weekly GLP-1 receptor agonists (semaglutide, tirzepatide, dulaglutide) for 3 weeks (21 days) and daily formulations (liraglutide) for 3–4 days before the procedure to minimize pulmonary aspiration risk from delayed gastric emptying. 1, 2

Evidence-Based Holding Periods by Formulation

Weekly Formulations

  • Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound): Hold for 3 weeks before elective surgery, as the half-life is approximately 7 days and three half-lives (≈88% drug clearance) are required to minimize aspiration risk. 1, 2
  • Dulaglutide (Trulicity): Hold for 2–3 weeks before surgery, with a half-life of 4.5–4.7 days. 1, 2

Daily Formulations

  • Liraglutide (Victoza, Saxenda): Hold for 3–4 days before surgery, with a half-life of approximately 13 hours. 1, 2

Oral Semaglutide (Rybelsus)

  • Oral semaglutide: Hold for 3 weeks (21 days) before elective procedures, as the half-life remains approximately one week regardless of administration route. 2

Why the American Society of Anesthesiologists' Original Recommendation Is Inadequate

  • The ASA initially recommended holding weekly GLP-1 receptor agonists for only 1 week before elective surgery, but emerging evidence demonstrates this is insufficient—discontinuation for 7 days did not decrease the prevalence of retained gastric contents. 1, 2
  • Gastric ultrasonography studies reveal that 24.2% of patients on semaglutide have residual gastric content versus 5.1% of controls, even after 12+ hour fasting periods and 10–14 days of medication discontinuation. 1, 2
  • Multiple case reports document pulmonary aspiration requiring ICU admission in patients who fasted 18–20 hours but stopped semaglutide only 4–6 days before surgery. 1, 2

Mechanism of Aspiration Risk

  • GLP-1 receptor agonists delay gastric emptying by inhibiting gastric peristalsis and increasing pyloric tone via vagal pathways, creating a persistent "full stomach" risk even with appropriate preoperative fasting. 1, 2
  • This delayed gastric emptying is documented even with long-acting formulations like semaglutide using scintigraphy, showing persistent effects despite some tachyphylaxis development. 3
  • The delayed gastric-emptying effect persists for 10–14 days after drug discontinuation, raising peri-operative aspiration risk independent of appetite-suppression effects. 3

Critical Distinction: Diabetes vs. Weight-Loss Indication

For Weight-Loss Patients (Non-Diabetic)

  • Hold medication for the full 3 weeks without exception, as the risks of continuing until shortly before surgery outweigh any benefits in patients using GLP-1 receptor agonists for weight management. 1, 2

For Diabetic Patients

  • Consult with the treating endocrinologist to weigh the risks and benefits of holding the drug for at least three half-lives, as prolonged cessation may have detrimental effects on perioperative glycemic control. 1, 2
  • The benefits of glycemic control in the perioperative period may outweigh the issues related to delayed gastric emptying in diabetic patients, requiring individualized risk-benefit assessment. 2
  • Consider bridging therapy (e.g., insulin or oral hypoglycemics) if the GLP-1 agent must be held longer than the next scheduled dose. 2

Risk Mitigation When Adequate Holding Period Not Achieved

If the medication has not been stopped for adequate duration, implement the following strategies:

  1. Consider postponement and rescheduling of the procedure to allow adequate medication clearance. 1, 2

  2. Perform point-of-care gastric ultrasound pre-operatively to assess for residual gastric contents (target gastric volume <1.5 ml/kg). 1, 2

  3. Administer prokinetic drugs such as metoclopramide or erythromycin pre-operatively to enhance gastric emptying. 1, 2

  4. Implement rapid-sequence intubation with full airway protection rather than supraglottic airways, as case reports show aspiration with supraglottic devices. 1, 2

  5. Treat the case as a "full stomach" scenario and apply standard aspiration-precaution measures (elevated head-of-bed, cuffed endotracheal tube). 2

  6. Consider pre-emptive gastric decompression (nasogastric tube) in patients judged to be at very high aspiration risk. 2

High-Risk Scenarios Requiring Extra Caution

  • Recent initiation or dose escalation of a GLP-1 agonist—patients who have recently started semaglutide or increased their dose are at higher risk and may require even longer discontinuation periods. 2
  • Presence of nausea, vomiting, or abdominal distention—procedures should be postponed until symptoms resolve. 2
  • Concurrent use of other gastric-emptying-delaying medications (opioids, proton pump inhibitors, tricyclic antidepressants). 2
  • Recent intake of recreational substances that slow gastric motility (alcohol, cannabis). 2
  • Patients with pre-existing digestive symptoms show significantly higher rates of gastric retention and require more than 21 days discontinuation. 1

Preoperative Documentation Requirements

Document the following in the preoperative assessment:

  • Indication and dose of GLP-1 receptor agonist. 1, 2
  • Date drug commenced, dose variations, and last dose taken. 1, 2
  • Symptoms of nausea, vomiting, or abdominal distention. 1, 2
  • Co-prescribed drugs that can delay gastric emptying (opioids, proton pump inhibitors, tricyclic antidepressants). 2
  • Recent intake of recreational drugs that delay gastric emptying (alcohol, cannabis). 2

Common Pitfalls to Avoid

  • Do not rely on standard fasting guidelines alone, as they are insufficient for patients on GLP-1 receptor agonists—retained gastric contents persist despite extended fasting. 2
  • Do not assume that one week of discontinuation is adequate, as emerging evidence demonstrates this is insufficient to eliminate aspiration risk. 1, 2
  • Avoid using supraglottic airway devices in patients who have not had adequate medication discontinuation, as case reports document aspiration events with these devices. 1, 2
  • Recognize that approximately 88% of the drug is cleared after three half-lives, but there is no strong evidence that gastric emptying fully normalizes after this time, so continued vigilance is required. 2

Guideline Limitations and Ongoing Vigilance

  • Standard pre-operative fasting guidelines alone are insufficient for patients on GLP-1 receptor agonists; retained gastric contents can persist despite extended fasting. 2
  • Although ≈88% of the drug is cleared after three half-lives, robust evidence that gastric emptying fully normalizes at that point is lacking; continued aspiration vigilance is advised. 2
  • The risk of aspiration during general anesthesia is unknown, but caution is advised in patients who recently commenced on GLP-1 receptor agonists. 4

References

2
Guideline

Semaglutide Holding Period Before Surgery to Reduce Aspiration Risk

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3
Guideline

Pharmacological Management of Obesity

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

How long should a patient with diabetes or metabolic syndrome, scheduled for open heart bypass surgery, be off Glucagon-like peptide (GLP) medications before the procedure?
How soon before surgery should GLP‑1 receptor agonist injections be stopped?
What are the guidelines for general anesthesia in patients taking Glucagon-like peptide-1 (GLP1) receptor agonists, such as semaglutide (Ozempic) or liraglutide (Victoza), with a history of diabetes mellitus and potential impaired renal or liver function?
How many hours before a surgery requiring general anesthesia should liraglutide (Victoza) be discontinued?
For a patient undergoing surgery on a given date, what is the latest time to administer a GLP‑1 receptor agonist injection (e.g., exenatide, liraglutide, dulaglutide, semaglutide)?
What is the recommended antibiotic regimen for an adult with infected renal and hepatic cysts who has no known drug allergies?
Should an adult with iron‑deficiency anemia (low ferritin, decreasing hemoglobin, low transferrin saturation) be referred for gastrointestinal endoscopic evaluation despite a negative fecal occult blood test?
Do I need formal pelvic‑floor physical therapy for internal anal sphincter hypertonicity, or can home stretching and sitz baths alone provide adequate relief?
In a 67-year-old man, does testosterone replacement therapy increase the risk of prostate cancer or venous thromboembolism?
What is pectoralis minor syndrome and what are the first‑line and second‑line management options?
In a premenopausal woman treated for hypoactive sexual desire disorder, does flibanserin (Addyi) need to be tapered before discontinuation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.